Alpha Lipoic Acid in Ulcerative Colitis

Launched by TANTA UNIVERSITY · Sep 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the use of a supplement called alpha-lipoic acid in combination with a medication known as mesalamine for people with mild to moderate ulcerative colitis (UC). Ulcerative colitis is a condition that causes inflammation in the colon, leading to symptoms like abdominal pain and diarrhea. Researchers believe that alpha-lipoic acid may help reduce inflammation and improve symptoms because of its antioxidant properties, which means it helps protect the body from harmful substances.

To participate in the trial, individuals must be at least 18 years old and have recently been diagnosed with active, mild to moderate ulcerative colitis. They should also be receiving treatment with mesalamine. However, people with severe ulcerative colitis, certain other health conditions, or those taking specific medications may not be eligible. Participants in the trial can expect to take the study medication in addition to their current treatment and will be monitored for any effects or changes in their condition. This study is currently recruiting participants, and it offers a chance to contribute to research that may improve treatment options for ulcerative colitis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years old.
• • Both male and female sex.
• • Newly diagnosed patients with active mild and moderate ulcerative colitis according to American College of Gastroenterology (ACG) Clinical Guideline for diagnosing Ulcerative Colitis in Adults.26
• • Patients treated with 5-aminosalisylic acid (mesalamine).
• Exclusion Criteria:
• • Patients with severe ulcerative colitis.
• • Patients with colorectal cancer.
• • Patients on rectal or systemic steroids.
• • Patients on immunosuppressants or biological therapies.
• • Patients with previously failed treatment with sulphasalazine.
• • Patients with known allergy to study medications.
• • History of complete or partial colectomy.
• • Patients with significant liver disease (fibrosis, cirrhosis, NASH, NAFLD).
• • Patients with other inflammatory diseases.
• • Patients with thyroid diseases.
• • Patients with arrhythmia, ischemic heart disease, and heart failure.
• • Patients with diabetes.
• • Patients on antioxidants supplement (vitamin A, C, E), selenium, co-enzyme Q.
• • Patients on amlodipine, levothyroxine, low strength aspirin, warfarin, atorvastatin, insulin, oral hypoglycemic, chemotherapy (drug-drug interaction).